☆ 4.7 Article

Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England

BRITISH JOURNAL OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Health Care Sciences & Services

Promoting innovation while controlling cost: The UK's approach to health technology assessment

Michael Anderson et al.

Summary: This article reviews the United Kingdom's approach to appraising new health technologies, highlighting the contributions of NICE, SMC, and AWMSG. The study acknowledges limitations in the current approach and discusses potential challenges in accommodating personalized and genomic medicine in the future.

HEALTH POLICY (2022)

Add to Collection

Review Oncology

Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality

Amanda J. Kerr et al.

Summary: Adjuvant and neoadjuvant breast cancer treatments can decrease breast cancer mortality but may increase mortality from other causes. The benefits and risks of different treatment options have been evaluated using high-quality evidence to guide individual treatment decisions.

CANCER TREATMENT REVIEWS (2022)

Add to Collection

Article Oncology

Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis

Debra Patt et al.

Summary: This study describes the treatment patterns and effectiveness of PAL + AI in real-world clinical practice for HR + / HER2- metastatic breast cancer patients, and finds that initiating palbociclib at a dose of 125 mg/day is associated with improved outcomes.

CLINICAL BREAST CANCER (2022)

Add to Collection

Article Oncology

Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience

Benjamin James Hall et al.

Summary: This study aimed to evaluate the real-world efficacy and toxicity of neoadjuvant chemotherapy combined with dual HER2 directed therapy for HER2-positive breast cancer patients in a UK tertiary referral cancer center. The results showed that this combined treatment can effectively reduce tumor burden in patients, but the pCR rate is lower in ER and PgR-positive breast cancer.

BREAST JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019

Mark P. Lythgoe et al.

Summary: This study compared the market authorization dates for new oncology therapies approved in the US and Europe over the past decade, and examined and contrasted the regulatory activities of the FDA and EMA in the approval of new cancer medicines. The results showed that the US approved oncology therapies earlier than Europe, with the FDA receiving licensing applications sooner and having shorter review times.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Oncology

Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study

Salma El Badri et al.

Summary: The study aimed to investigate the tolerability and efficacy of palbociclib + AI in treating advanced breast cancer in patients over 75 years old, showing that the treatment is effective and well-tolerated in the older population. The clinical benefit rate was high, and dose reductions and delays did not affect survival outcomes. Geriatric and frailty assessments can help guide treatment decisions in these patients.

BREAST (2021)

Add to Collection

Article Medicine, General & Internal

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Avi Cherla et al.

Summary: This study compared FDA accelerated approval decisions for cancer drugs with NICE coverage decisions, revealing that 30 cancer drug indications granted accelerated approval by the FDA were not subsequently reviewed by European regulators or NICE, and 12 drugs were denied authorization or coverage due to insufficient safety, clinical efficacy, or cost-effectiveness. Coverage of cancer drugs by the National Health Service commonly required additional price concessions, restrictions to approved indications, or review of additional data.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018

Mengyuan Fu et al.

Summary: The study found that between 2011 and 2018, the proportion of US residents with employer-sponsored insurance who were dispensed new cancer drugs without documented overall survival benefit increased significantly, accounting for substantial spending.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center

Michela Piezzo et al.

Summary: This study investigated the use of trastuzumab biosimilars at a National Cancer Institute over a period of two years, showing a high proportion of biosimilar use in treatment and no significant differences in adverse drug reactions compared to reference drugs. Additionally, cost savings of over 800,000 euros were achieved in the first two years, with estimates of further increasing savings over time.

PHARMACEUTICS (2021)

Add to Collection

Article Multidisciplinary Sciences

Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice

Sushmita Rath et al.

Summary: This study investigated the efficacy and safety of palbociclib and ribociclib in routine clinical practice for metastatic breast cancer in India, finding that the outcomes were in line with expectations from pivotal trials in terms of both effectiveness and toxicity.

PLOS ONE (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience

Katalin Boer et al.

Summary: This nationwide retrospective study in Hungary provides insights into the real-world use of the CDK4/6 inhibitor palbociclib in a large population of advanced breast cancer patients. The findings confirm the good tolerability of palbociclib with similar dose reduction rates to those reported from registration trials.

ONCOTARGETS AND THERAPY (2021)

Add to Collection

Article Oncology

Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices

Junji Lin et al.

Summary: This study reviewed the real-world use of palbociclib-based therapy in patients with advanced/metastatic breast cancer in US community oncology clinics. The findings were consistent with previous studies, showing positive outcomes in patients treated with palbociclib in combination with hormone therapy drugs.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset

Chloe J. Bright et al.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)

Add to Collection

Article Oncology

Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England

Melissa Ruth Gannon et al.

JOURNAL OF GERIATRIC ONCOLOGY (2020)

Add to Collection

Article Oncology

FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis

Chandra P. Leo et al.

CANCERS (2020)

Add to Collection

Article Health Care Sciences & Services

Real-world evidence use in assessments of cancer drugs by NICE

Ash Bullement et al.

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Treatment variation in early breast cancer in the UK

David Dodwell et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Oncology

Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

Peter A. Fasching et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Review Oncology

Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States

Emily M. Miller et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis

Helen J. Curtis et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Review Oncology

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

Kimberly Blackwell et al.

CLINICAL BREAST CANCER (2018)

Add to Collection

Editorial Material Medicine, General & Internal

NICE, the NHS, and Cancer Drugs

Andrew Dillon et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Medicine, General & Internal

Cohort profile: prescriptions dispensed in the community linked to the national cancer registry in England

Katherine E. Henson et al.

BMJ OPEN (2018)

Add to Collection

Letter Health Care Sciences & Services

Assessing the impact of NICE guidance on the prescribing of hormonal treatments of breast cancer in England

Raymond W. Fitzpatrick et al.

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2015)

Add to Collection

Article Social Sciences, Mathematical Methods

Conducting interrupted time-series analysis for single- and multiple-group comparisons

Ariel Linden

STATA JOURNAL (2015)

Add to Collection

Article Surgery

Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score

J. N. Armitage et al.

BRITISH JOURNAL OF SURGERY (2010)

Add to Collection

Article Medicine, General & Internal

The role of NICE technology appraisal in NHS rationing

Simon Walker et al.

BRITISH MEDICAL BULLETIN (2007)

Add to Collection

Article Medicine, General & Internal

What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews

TA Sheldon et al.

BMJ-BRITISH MEDICAL JOURNAL (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.